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PRM59
HeMatoPoietic steM cell tRansPlantation outcoMes: logistic 
RegRession Model develoPMent
Hatfield M.D.1, Kramer M.A.2, Johnson M.L.1
1University of Houston, Houston, TX, USA, 2The University of Texas MD Anderson Cancer Center, 
Houston, TX, USA
Objectives: The objective was to determine the most effective logistic regres-
sion models in terms of explaining the greatest amount of variance regarding four 
outcomes: graft versus host disease (GVHD), liver toxicity, neurotoxicity, and mor-
tality, among a cohort of patients undergoing hematopoietic stem cell transplanta-
tion. MethOds: Busulfan is used in combination with fludarabine or clofarabine 
as part of an effective chemotherapy based myeloablative preparative regimen for 
patients undergoing stem cell transplantation. Pharmacokinetic data regarding 
patient busulfan clearance was used in the analysis, since dosing is very sensi-
tive. Other clinically relevant covariates included: age, gender, race, primary can-
cer diagnosis, type of transplant (autologous or allogeneic), and prior transplant 
history. Descriptive statistics and logistic regression analyses were performed to 
assess the effect of these variables on each of four outcomes: GVHD, liver toxic-
ity, neurotoxicity, and mortality. Hosmer and Lemeshow goodness-of-fit tests and 
c-statistics were used to optimize the models. Only aggregate level information 
was reported. Statistical significance was set at 0.05. Results: Data on a cohort of 
752 patients undergoing hematopoietic stem cell transplantation were collected. 
Most patients were: 46.7±15.8 years old, male (59.8%), Caucasian (68.6%), with acute 
myeloid leukemia (28.9%), underwent an allogeneic transplant (67.0%), and had not 
received a prior transplant (93.5%). Controlling for the covariates listed, the mod-
els resulted in Hosmer and Lemeshow goodness-of-fit test statistics (chi-square, 
number of degrees of freedom, p-value) for each dependent variable as follows: GVHD 
(2.57, 5, 0.77); liver toxicity (5.17, 8, 0.74); neurotoxicity (8.45, 8, 0.39); and mortality 
(5.95, 8, 0.65). The c-statistics for each model were: GVHD (0.87); liver toxicity (0.74); 
neurotoxicity (0.75); and mortality (0.72). cOnclusiOns: The logistic regression 
models used were effective in determining the outcomes of GVHD, liver toxicity, 
neurotoxicity, and mortality, among a cohort of patients undergoing hematopoietic 
stem cell transplantation.
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tHe estiMate of vaccination coveRage Rate using tRansMisson 
dynaMic Model: a exaMPle of PneuMococcus vaccines
Chang C.J.1, Wen Y.W.2, Fann C.S.J.3
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Objectives: Vaccination coverage rate is usually obtained from the decision of 
an immunization policy. Actual impacts to the outcomes by different vaccinated 
recipients selection and their coverage rates were seldom discussed. This study 
aims to use a transmission dynamic model (TDM) based on a system of differen-
tial equations in susceptible-infectious-recovered model to optimally explore the 
estimates of coverage rates. MethOds: 23-valent pneumococcal polysaccharide 
vaccines (PPV23) and 13-valent pneumococcal conjugate vaccines (PCV13) have been 
shown their cost-effectiveness in elderly and children, respectively. Scenarios of 
PPV23 to the elderly aged 65+ years and PCV13 to children aged below 4 years were 
assumed and TDM was used. All epidemiological parameters were obtained from the 
Taiwan’s National Health Insurance Database and the vaccine efficacy was obtained 
from the literatures. Various vaccination coverage rates were considered. The equa-
tions were solved using the fourth-order Runge–Kutta method implemented in R 
Statistical Software. Results: The estimates of PPV23 for the elderly and PCV13 
for the children were both 70% to achieve optimal goal. Increasing the rate over 
70% will not significantly decrease the total number of pneumonia infection and 
death but increase the costs. cOnclusiOns: This study proposed an approach 
to estimate the optimal vaccination coverage rate based on the TDM simulations. 
This will provide value-based information of vaccination policy in the decision of 
vaccine quantity and recipients.
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PHysicians’attRibutes and ReveRsed conjoint analysis
Huttin C.
ENDEPUSresearch,Inc, Cambridge, MA, USA
Objectives: The objective of this paper is the analysis of practice or 
physicians’attributes in addition to patient or products ‘attributes to explain pat-
terns of drug utilization in predictive disease models including reversed conjoint 
data. In previous European physicians’cost sensitivity studies, physicians’ charac-
teristics such as demographics, solo/group practices, types of remuneration, location 
(depressed/wealthy areas) were not conclusive (ENDEP/biomed, 2003). This analysis 
explores additional physicians’attributes more related to professional activities 
(Rischatsch Zweifel,2012) such as referrals or restrictions to specialists, quality obli-
gations and incident reporting. MethOds: Different types of physicians’ choice 
sets are designed with sets of attributes classified in subgroups Z1,Z2,Z3 ( Z1 for 
products, Z2 for patients, Z3 for physicians’ attributes) . A sample of 688 patients 
diagnosed with diabetes type II without complications (ICD 250.00) is extracted 
from the National Medical Care Survey (Huttin/Wong, 2010). Practices are grouped 
by stages of IT computerization for billing and EMRs. Pharmacological treatment 
(including oral, injectables and supplies) is defined with a drug list from Facts and 
Comparisons over three successive years (e.g. 2004/2005/2006) for a 2005 database. 
Physicians’treatment choices are analyzed with a disease model integrating Z3 
physicians’attributes on subsets of physicians. The cumulative logistic model is 
run with SAS. Results: Results of the predictive disease model on diabetes type 
II show on the 2005 analytical dataset that drug utilization is much lower when 
physicians in clinical practice use a referral process (0.46). The stage of computeri-
zation of practices especially with ebilling remains highly significant (lower drug 
utilization when ebilling is used (0.69)). Additional runs are tested with predictive 
models on other chronic conditions (Asthma and Hypertension). cOnclusiOns: 
Objectives: CDC guidelines recommend hepatitis C virus (HCV) screening for 
the 1945-1965 birth cohorts. Since HCV prevalence is decreasing with birth-year, 
age-specific screening is less cost-effective in later cohorts. To inform the optimal 
time to discontinue screening, collecting additional information may be valu-
able, though when this information should be collected is unclear. MethOds: 
We apply a Markov decision process framework to evaluate how long to continue 
HCV screening in US men. We identify the optimal information collection policy 
for two parameters assumed constant across cohorts - reductions in quality-of-
life from awareness of HCV-positive status and the fibrosis-stage distribution at 
screen-detected diagnosis at age 50 - alone and in combination with information 
collection about HCV prevalence which is decreasing across cohorts. We estimate 
lifetime costs and benefits using a previously-developed HCV screening model and 
HCV prevalence dynamics derived from NHANES. The assumed willingness-to-
pay threshold is $75,000 per QALY. Results: The presence of a parameter which 
varies across cohorts influences the per-person value-of-information about both 
time-varying and static parameters. In these cases, we show analytically that it 
may be optimal to delay information collection. Given our prior beliefs, the optimal 
strategy is to collect sample information about the reduction in quality-of-life 
from awareness of HCV-positive status immediately and then, depending on the 
result of that study, collect information on HCV prevalence 3 to 20 years in the 
future. This strategy increases the expected incremental net monetary benefit by 
$2.3 million compared to a strategy of collecting information about both immedi-
ately. cOnclusiOns: We demonstrate that when parameters vary across cohorts, 
the optimal information collection policy, for both time-varying and static param-
eters, may be to delay information collection until it is more likely to influence 
the decision. Our dynamic programming framework enables the consideration of 
delayed information collection in numerous contexts.
PRM57
fRontieRs in PediatRic HealtH tecHnology assessMent: develoPMent 
of a discRete event siMulation Model foR econoMic evaluation of 
scReening, diagnosis and tReatMent stRategies in autisM sPectRuM 
disoRdeR
Zur R.M., Carter M.T., Scherer S.W., Ungar W.J.
Hospital for Sick Children, Toronto, ON, Canada
Objectives: There are few economic evaluations of strategies for screening, 
diagnosing, and treating autism spectrum disorder (ASD). The objective of this 
study was to create a discrete event simulation (DES) model of the pathway of 
care for children with suspected ASD up to age 6. This model will be used to 
perform economic evaluations of screening protocols, diagnostic tests and treat-
ments for ASD. MethOds: A DES model was conceived to simulate a Canadian 
population of children with suspected ASD. Attributes important for simulation 
of entities were identified from the literature and expert opinion. Important 
categories of attributes included ASD risk factors, ASD co-morbidities, meas-
ures of development, and measures of severity of ASD. The pathway of care 
was created with review of current practice guidelines as well as consultation 
with developmental pediatricians. Queuing for screening, diagnosis, and treat-
ment comes from entities accessing limited resources over a period of time. 
We will use calibration techniques to set resource and time limits to match 
the wait times reported in the literature. Results: A DES model was built for 
children with suspected ASD up to age 6. The DES model addresses population 
heterogeneity by including risk factors such as gender, autistic siblings, and older 
parents, genetic co-morbidities, and physical and psychological co-morbidities. 
The DES model simulates outcomes in terms of ASD severity, IQ, and language 
skills. The DES model addresses the issues of wait times that are relevant in 
ASD screening, diagnosis, and treatment by having entities queue for limited 
resources. cOnclusiOns: The DES modelling approach is well-suited to model-
ling the pathway of care for ASD patients. Patients with ASD have a wide variety 
of disabilities and co-morbidities that can be captured in DES modelling. DES 
modelling is also able to address issues of wait times that are prevalent in ASD 
screening, diagnosis, and treatment.
PRM58
PRedicting HeaRt failuRe RecuRRence afteR aoRtic valve 
RePlaceMent using a coMPeting-Risks Model
Chan V1, Anderson L.H.2, Martinson M.3, Koullick M.3, Ruel M.1
1University of Ottawa Heart Institute, Ottawa, ON, 2Technomics Research, Ottawa, ON, 3Ottawa, 
ON
Objectives: Congestive heart failure (CHF) is a major health burden with an 
increasing prevalence and incidence. Risk factors associated with recurrent CHF 
following surgical AVR has been previously described in a multivariate model by 
Ruel et al. The objective of this study was to re-create the previously described 
model without relying on the initial patient-level data. MethOds: The semipara-
metric Cox proportional hazards models described by Ruel et al. was based upon 
1563 patients who underwent AVR at the University of Ottawa Heart Institute 
between 1976 and 2001. Adjusted hazard ratios and mean covariate values were 
reported. Several distributions, including exponential, Weibull, and competing-
risks, were tested to determine, which would better reproduce the recurrent CHF 
function. Results: All candidate models successfully reproduced the published 
results by Ruel et al. One model was converted into a customizable excel model. 
Clinically relevant variables included in the re-created model included valve size, 
mean transprosthesis gradients, patient age, atrial fibrillation, preoperative NYHA 
class, body surface area, coronary artery disease, and smoking. After adjustment 
of patient and valve characteristics, the model predicted freedom from recur-
rent HF in the Ruel Cohort at 1, 5, 10, and 15 years as 98.4%, 90.8%, 73.2%, and 
43.5% compared with published values of 98.6%, 88.6%, 73.9%, and 45.2%, respec-
tively. cOnclusiOns: The re-created model accurately predicted CHF recurrence. 
Statistical models validated using large patient cohorts can be useful in population 
management.
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exchange rate fluctuations, country’s attributes modification, and drug price 
changes. Each price evaluation event implied the calculation of a new drug price 
and the model generated drug price evolution in each country over time. Model 
inputs were obtained from a literature review and consultation of representatives 
of competent authorities and international organizations. The model was validated 
by assessing actual drug prices at launch and over time for 53 randomly selected 
medicines. This model was developed for the EU Commission. Results: The model 
could be used to assess the impact of pricing policies. For example, it showed that 
the price erosion predicted under the effects of ERP only was for most products 
slower than observed in reality, and thus that price negotiations also importantly 
contributed to price erosion. It can also be used to compare alternative launch 
sequences. The simulated price trends over time were consistent with observed 
trends. cOnclusiOns: This DES model is the first comprehensive ERP published 
model across drug life cycle that allows testing various policy scenarios and predict 
impact of ERP in the real-life. This flexible model may prove useful tool to support 
decision making from the perspective of authorities or industry.
PRM65
Review of Models used in econoMic analyses of new oRal 
tReatMents foR tyPe 2 diabetes Mellitus
Asche C.1, Eurich D.T.2, Hippler S.1
1University of Illinois, Peoria, IL, USA, 2University of Alberta, Edmonton, AB, Canada
Objectives: This study aimed to provide insight into the utilization of cost-effec-
tiveness modeling methods. The focus of our study was aimed at the applicability 
of these models, particularly around the major assumptions related to the clinical 
parameters used in the models, and subsequent clinical outcomes. MethOds: 
MEDLINE and EMBASE were searched from 1 January 2004 to 14 February 2013 in 
order to identify published cost-effectiveness evaluations for the treatment of T2DM 
by new oral treatments (GLP-1 receptor agonists and DPP-4 inhibitors). Once iden-
tified, the articles were reviewed and grouped together according to the type of 
model and study comparators. Results: A total of 15 studies were identified in 
our review. Nearly all of the models utilized a health care payer perspective and 
provided a lifetime horizon. The CORE Diabetes Model, UKPDS Outcomes Model, 
Cardiff Diabetes Model, CDC Diabetes Cost- Effectiveness Group Model and Diabetes 
Mellitus Model were cited. Nearly all of the studies made significant assumptions 
surrounding the impact of GLP-1 receptor agonists or DPP-4 inhibitors on clinical 
parameters and subsequent short- and long-term outcomes. The impact of these 
clinical changes often resulted in large lifetime changes in health outcomes in the 
models. The validity of these projections, particularly for the longer time frames, 
is questionable. cOnclusiOns: Future models should aim to include all relevant 
treatment outcomes, whether these relate to effects on underlying diabetes and 
its complications or to short- or long-term side effects of treatment. We need to 
explore why cost-saving interventions could benefit further from adding patient 
characteristics, which may be able to better predict the use of lower-cost alterna-
tives. Moreover, the vast array of different clinical, cost and utility data used in the 
different models reviewed makes it apparent that a uniform methodology should 
be developed for diabetes economic models.
PRM66
estiMating tHe tiMe tRade-off values of tHe eQ-5d-5l HealtH states 
in uRban cHina
Luo N.1, Liu G.2, Li M.3
1National University of Singapore, Singapore, Singapore, 2Peking University, Beijing, China, 
3University of Maryland School of Pharmacy, Baltimore, MD, USA
Objectives: The EQ-5D-5L is a new health-state classification system consisting of 
five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/
depression), with each dimension described into five problem levels (no, slight, mod-
erate, severe, and extreme). This study aimed to estimate the time trade-off (TTO) 
values of the 3,125 EQ-5D-5L health states to urban residents in China. MethOds: 
The values for 86 selected EQ-5D-5L health states were elicited using the ‘com-
posite’ TTO technique from a general population sample (n= 1,250) drawn from 5 
Chinese cities. In computer-assisted personal interviews, participants each valued 
a randomly selected block of health states (n= 10). Various function forms were con-
structed to specify the possible relationship between TTO values and health-state 
characteristics and estimated using linear regression models. The function form 
exhibiting the best fit of the data and the least prediction biases was identified to 
estimate the values of all EQ-5D-5L health states. Results: The Hausman test sug-
gested that random effects estimator was more efficient than fixed effects estimator 
for all function forms. The best model comprised a constant and twenty-one dummy 
variables indicating the presence or absence of specific problems or patterns of 
problems in a given EQ-5D-5L health state, including nineteen for all individual 
health problems except for slight anxiety/depression, one for severe or extreme 
problems in any functional dimensions, and one for the 5 mildest EQ-5D-5L health 
states. According to the final model, the mean absolute error of the predicted val-
ues for the 86 health states was 0.032 and the range of all the predicted values was 
-0.339 to 0.893. cOnclusiOns: Values of EQ-5D-5L health states can be estimated 
using time trade-off values of a small portion of the health states. The EQ-5D-5L 
preference values estimated in this study may be used as quality-of-life weights in 
cost-utility analysis of health technologies and programs in China.
PRM67
identifying and cHaRacteRizing tRajectoRies of Qol in PeRsons witH 
advanced canceR: iMPoRtant contRibutoRs to decReasing Qol in 
PeoPle witH canceR
Rodriguez A.M., Gagnon B., Mayo N.E.
McGill University, Montreal, QC, Canada
Objectives: In cancer, we aim at maintaining the Quality of Life (QOL) of patients. 
Yet minimal work examines predictors of QOL constructs over time. The aim of this 
study was to explore the temporal sequence leading to optimal QOL over time of key 
The inclusion of physicians’attributes is critical for discrete choice experiments. 
This study identifies some statistically significant attributes such as the referral 
process. It confirms previous results by Miele, Weiland and Dungan (2012) showing 
how patient can benefit from reduction in HbA1C with centralized referral. Further 
development investigates how significant physicians’ attributes can impact reversed 
conjoint modeling results on physicians’ cost sensitivity.
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incoRPoRating a PHaRMacoMetRic Model-based Meta-analysis into a 
HealtH econoMic MicRosiMulation Model of coPd
Slejko J.F.1, Ribbing J.2, Willke R.J.3
1University of Washington, Seattle, WA, USA, 2Pfizer, Silverdal, Sweden, 3Pfizer, Inc., New York, 
NY, USA
Objectives: The study objective was to utilize a pharmacometric model-based 
meta-analysis (PMBMA) within a health economic microsimulation model 
(HEMM) of chronic obstructive pulmonary disease (COPD). PMBMA is a type of 
meta-regression which employs non-linear models estimated on trial-level data 
to relate patient and trial characteristics, dosing, surrogate markers, and outcomes 
effects of treatment. MethOds: A Markov microsimulation model was developed 
to estimate monthly changes in the key disease severity metrics of COPD (FEV1 
and exacerbations) in order to compare a hypothetical drug that increases FEV1 to 
usual care. The PMBMA was used to predict a baseline exacerbation rate in a group 
of actual trial patients, given their known baseline FEV1. The hypothetical drug 
increased baseline FEV1, thereby decreasing the exacerbation rate in the hypo-
thetical drug arm vis-à-vis the individual PMBMA predictions. Individual patient 
microsimulations and model memory allowed the rate monthly FEV1 decline to 
vary by patient and by month allowing for stochastic improvements. Validation 
of trial-level PMBMA estimates used in predictions was performed. Issues of syn-
chronizing non-COPD mortality and common random numbers in microsimulation 
models were addressed. Results: In a sample of 376 trial patients with a mean 
FEV1 (percent predicted) of 55%, had an exacerbation rate of 0.7 exacerbations per 
year, as predicted by the PMBMA. A drug that increased FEV1 at baseline by 30 mL 
resulted in a 21% decrease in exacerbations, while a 50 mL increase resulted in a 26% 
decrease. Given a simplified estimation of costs and QALYs associated with COPD, 
a drug with a 50 mL increase costing 40 Euro per month had an ICER of 46,736 Euro/
QALY. cOnclusiOns: The synergistic aspects of PMBMA and HEMM are highlighted 
in this hypothetical example. Markov microsimulation modeling allows the finer 
predictions of PMBMA to inform parameters while individual simulations allow 
advantages of model memory.
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a guide on How to sPeeduP coMPutation tiMe in ce-Models using vba 
oR Multi-PRocess PRogRaMMing in c++
Khorshid M., Thuresson P.O., Ray J.
F. Hoffmann-La Roche Ltd., Basel, Switzerland
Objectives: There is a trend of health economic models (HEM) becoming computa-
tionally expensive. Additionally, less complex HEMs increasingly include some type 
of computationally demanding analysis like value of information (VOI; e.g. EVPI, 
EVPPI). However, the computation time required to perform such analyses are often 
stated as the primary constraint. Our objective was to determine whether efficiency 
could be achieved using programming languages and multi-process programming 
to substantially speedup the simulation time for HEMs. MethOds: Two different 
techniques were applied, firstly an implementation solely in VBA, secondly paral-
lel computing implementation in C++. The general complexity of VOI-analysis in 
HEMs algorithms is due to nested loops. Multi-process programming is suitable for 
these tasks as it decomposes complex routines into small parts which are solved 
concurrently. A publicly available hip-replacement Markov model in Excel® served 
as a blueprint. It was reconstructed using the two aforementioned techniques, both 
replicas used the spreadsheet application as the interface, but calculations were 
performed in their respective programming environments. The computational time 
required to perform the EVPPI-analysis for each one of these techniques were com-
pared. All computations were performed in an identical computational environ-
ment. Outcomes were compared to ensure there were no systematic differences in 
the underlying calculations. Results: The VBA implementation of the hip-replace-
ment model reduced simulation time by up to 7X compared to the original model. 
The improvement for the multiprocessing in C++ was 10X compared to the VBA 
implementation when running on a quad-core environment. cOnclusiOns: This 
study demonstrated that the computation time of the selected HEM was improved 
considerably using the same language, primarily by minimizing the communication 
between VBA and spreadsheet. A more substantial improvement (~70X) was gained 
when using the multiprocessor capabilities in C++ combined with machine-level 
optimization. However, to achieve this speedup, more development time and may 
accompany reluctance due to specialist programming expertise.
PRM64
a Model siMulating exteRnal RefeRence PRicing to suPPoRt Policy 
decision Making in euRoPe
Vataire A.L.1, Cetinsoy L.2, Rémuzat C.3, Aballea S.3, Toumi M.4
1University of Lyon 1, Villeurbanne, France, 2Creativ-Ceutical, PARIS, France, 3Creativ-Ceutical, 
Paris, France, 4University Claude Bernard Lyon 1, Lyon, France
Objectives: The objective of this project was to build a model simulating the exter-
nal reference pricing (ERP) process, applied to the 28 European Union Member States, 
Iceland, Norway and Switzerland, to understand the price dynamics of ERP-based 
systems and predict the consequences of various ERP policy scenarios. MethOds: 
A discrete-event simulation (DES) modelling approach was adopted. This approach 
allowed for fixed ERP rules and quick dynamic changes. Three groups of attributes 
were included in the model: ERP policy attributes, drug attributes and countries’ 
economic attributes. Occurrences of the following events were simulated: drug 
launch and first price setting, pricing decisions using ERP in different countries, 
